FDA clears Protego's pivotal trial of PROT-001 for AL amyloidosis

Overview

Updated 59 minutes ago

The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a pivotal Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. The oral drug will be tested as an add-on to standard plasma cell-directed therapy, which is currently the backbone of treatment.

AL amyloidosis is a rare, often fatal disease in which misfolded light chain proteins clump in organs, especially the heart. Existing therapies destroy the plasma cells that make the faulty proteins, but patients relapse when those cells return. PROT-001 works differently: it binds to and stabilizes light chains so they cannot misfold, attacking the disease at its root. No protein stabilizer has ever been approved for light chain amyloidosis.

Why it matters

If PROT-001 works, AL amyloidosis patients get the first therapy that stops protein misfolding itself, not just the cells that make faulty proteins.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$130M

Series B funding

Oversubscribed round led by Novartis Venture Fund and Forbion to fund pivotal development.

100+

Phase 1 healthy volunteers

Placebo-controlled first-in-human study run in Australia in 2025.

~80%

Lambda light chain share

Lambda is the predominant light chain in AL amyloidosis; SHIELD-AL targets lambda patients.

599

Patients in retrospective study

The PRO-AL-001 retrospective study spanned 599 AL amyloidosis patients.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Brent J. Warner

Chief Executive Officer, Protego Biopharma

Leading the company into pivotal development

Jae B. Kim, MD

Chief Medical Officer

Appointed 2026; shepherding SHIELD-AL

Jeffery Kelly

Co-founder; Scripps Research professor

Scientific founder behind PROT-001

Chris Weyrer, MD, PhD

Principal at Vida Ventures; acting Chief Business Officer

Board seat at Protego

Organizations Involved

Protego Biopharma

Clinical-stage biotechnology company

Lead candidate PROT-001 cleared for pivotal trial

San Diego clinical-stage biotech developing small molecules that stabilize protein folding to treat systemic amyloid diseases.

U.S. Food and Drug Administration

Federal Regulatory Agency

Cleared PROT-001 investigational new drug application

The US FDA cleared the investigational new drug application enabling Protego to start the SHIELD-AL pivotal study.

Timeline

2017 October 2026

6 events Latest: Today

Tap a bar to jump to that date

October 2026
FDA clears IND
Today Regulatory

FDA clears investigational new drug application; SHIELD-AL pivotal study authorized.
Today
January 2026
Phase 2/3 plans set
Planning

Company plans pivotal trial for AL amyloidosis in the second half of 2026.
January 5th, 2026
December 2025
Phase 1 completes
Clinical Trial

Phase 1 study in volunteers completes in Australia under NCT06981299.
December 23rd, 2025
Series B raised
Funding

Oversubscribed $130M round closes, led by Novartis Venture Fund and Forbion.
December 1st, 2025
2025 Q2
Phase 1 begins
Clinical Trial

First-in-human trial of PROT-001 starts in healthy volunteers in Australia.
2025 Q2
2017
Protego founded
Founding

Protego Biopharma founded in San Diego to develop protein-stabilizing drugs for misfolding diseases.
2017

Scenarios

Positive SHIELD-AL interim data; PROT-001 heads to FDA filing

Likely Resolves by Q2 2028

Discussed by: Protego leadership; BioPharma Dive analysis of the Series B

SHIELD-AL pairs PROT-001 with standard-of-care plasma cell therapy in newly diagnosed lambda AL amyloidosis patients. The company's stated goal of pursuing accelerated and full approval, plus the appointment of a regulatory-seasoned CMO, signal confidence. Positive interim results showing deeper or faster responses would make PROT-001 the first protein stabilizer approved for light chain amyloidosis.

SHIELD-AL enrollment or program hits a delay

Possible Resolves by Q2 2027

Discussed by: AdisInsight pipeline tracking; standard rare-disease trial timelines

Pivotal trials in rare diseases often lag on enrollment, especially with an add-on control. Any FDA clinical hold, supply problem or slow site activation would push the timeline past company guidance. Enrollment status on ClinicalTrials.gov is the clearest signal of a slip.

PROT-001 fails pivotal endpoint; program wound down

Uncertain Resolves by Q2 2029

Discussed by: Standard drug development risk; analysts noting limitations of current therapy

If the interim or final analysis shows no added benefit over standard of care alone, the add-on design would likely be discontinued. The company has framed PROT-001 as potentially paradigm-shifting; a miss would leave AL amyloidosis without its first stabilizer and raise questions about the chaperone approach in light chain disease.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

September 2019

Tafamidis (Vyndamax) approval for transthyretin amyloidosis (2019)

Tafamidis, discovered by FoldRx and acquired by Pfizer, stabilized transthyretin to stop it misfolding and depositing in the heart. The FDA approved it as Vyndamax in 2019, the first drug for transthyretin amyloid cardiomyopathy.

Then

Became a blockbuster, generating billions in annual sales and changing care for a disease once seen as untreatable.

Now

Validated the chaperone concept that Protego's Jeffery Kelly helped build; tafamidis remains standard therapy.

Why this matters now

Vyndamax is the same mechanism class PROT-001 targets, but for transthyretin, not immunoglobulin light chains. Its commercial success set the template Kelly's newer company hopes to repeat.

January 2021

Daratumumab (Darzalex) approval for AL amyloidosis (2021)

Daratumumab, a plasma cell-depleting antibody, won FDA approval for AL amyloidosis in 2021 after the Andromeda trial showed it improved responses when added to chemotherapy.

Then

Became the backbone of AL amyloidosis care, giving patients a more effective option than earlier regimens.

Now

Established the standard of care PROT-001 is designed to complement, not replace.

Why this matters now

SHIELD-AL adds PROT-001 on top of this very backbone, testing whether protein stabilization yields deeper, faster responses than cell depletion alone.